Roivant (ROIV) Director Meghan Fitzgerald Receives RSUs & Options

What Happened

• Meghan Fitzgerald, a director of Roivant Sciences Ltd. (ROIV), received two equity awards on 2026-09-16: 5,054 restricted stock units (RSUs) and a stock option award covering 10,531 shares. Both grants show a grant price of $0.00 (compensation awards), so no cash was paid or received at grant.

Key Details

• Transaction date: 2026-09-16; Form filed: 2026-09-18.
• RSUs: 5,054 shares granted at $0.00; scheduled to vest 100% on September 16, 2027, subject to continued service (Footnote F1).
• Options (derivative): award for 10,531 shares at $0.00; scheduled to vest and become exercisable 100% on September 16, 2027, subject to continued service (Footnote F2).
• Total reported cash value at grant: $0 (compensation awards, not purchases).
• Shares owned after the transactions: not disclosed in the filing.
• Filing timing: transaction reported on 9/16 and filed on 9/18; no late-filing flag noted in the filing provided.

Context

• RSUs are compensation that convert into shares only after vesting; they do not represent immediately tradable shares. The option award is a grant of the right to buy shares in the future if and when the option is exercised—no exercise occurred here.
• These entries are routine director compensation and do not by themselves indicate the director bought or sold company stock. There is no indication in the filing of a 10b5-1 plan, tax withholding sale, or immediate cashless exercise.